It owed that inspiration to a dogged UCLA researcher named Dennis Slamon (see box, p. 126).

FORBES: Cover Story

Slamon studied tumors from cancer patients in a search for clues to key cancer-causing genes and proteins.

FORBES: Targeting Tumors

This was controversial at first, but Slamon persuaded Genentech to test a monoclonal antibody that would block this protein.

FORBES: Targeting Tumors

UCLA's Jonsson Cancer Center oncologist Dennis Slamon thinks he knows why Iressa flopped in two large trials: lack of targeting.

FORBES: Targeting Tumors

Slamon was the force behind the first in a new generation of targeted cancer therapies: Herceptin, for advanced breast cancer.

FORBES: Targeting Tumors

Now Slamon pushes a new diagnostic test to spot the HER-2 gene.

FORBES: Targeting Tumors

The year ended particularly badly for activists when the White House reversed its political opposition to approving the first animal genetically modified for human consumption, a GM slamon that scientists at the Food and Drug Administration had determined was perfectly safe and nutritious.

FORBES: Connect